Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prednisolone Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 13/20 | 0.76 |
| ▸ | PGR | P06401 | 4/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | AR | P10275 | 2/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | TNF | P01375 | 1/20 | 0.76 |
| ▸ | IL6 | P05231 | 1/20 | 0.76 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.76 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.76 |
| ▸ | GLUL | P15104 | 1/20 | 0.76 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.76 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prednisolone Phosphoric Acid SCHEMBL21152848 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL21152533 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL26490459 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL13130881 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL20451347 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL7512 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL24622433 | 1.00 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| Prednisolone Phosphoric Acid SCHEMBL5483617 | 0.99 | PGR (0.77) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| SCHEMBL3634790 | 0.95 | PGR (0.78) | PGRHIF1ANR3C1HSD17B10CYP3A4 | |
| SCHEMBL20451346 | 0.95 | PGR (0.81) | PGRHIF1ANR3C1HSD17B10CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4721214-A1 | SYSTEM FOR CONTROLLING A CHARGE AND/OR DISCHARGE POWER OF AT LEAST ONE ENERGY STORE | Enspired GmbH (AT) | 2026-04-08 | — | — | EP | claimed |
| US-20250002591-A1 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHERMATOSUS PATIENTS | ASTRAZENECA AB (SE) | 2025-01-02 | — | — | US | claimed |
| WO-2024251811-A1 | SYSTEM FOR CONTROLLING A CHARGE AND/OR DISCHARGE POWER OF AT LEAST ONE ENERGY STORE | enspired GmbH (AT) | 2024-12-12 | — | — | WO | claimed |
| EP-4412641-A2 | TREATMENT OF LUPUS | Astrazeneca AB (SE) | 2024-08-14 | — | — | EP | claimed |
| US-20240252446-A1 | DERIVATIZED COLLAGEN-HYALURONIC ACID BASED IMPLANTS FOR SUSTAINED DELIVERY OF OPHTHALMIC DRUGS | SUSTAINED DRUG DELIVERY LLC | 2024-08-01 | — | — | US | claimed |
| EP-4377349-A1 | TREATMENT OF LUPUS | Astrazeneca AB (SE) | 2024-06-05 | — | — | EP | claimed |
| US-20240176122-A1 | DEVICES, SYSTEMS, AND METHODS FOR TREATING EAR DISORDERS | SPIRAL THERAPEUTICS INC. | 2024-05-30 | — | — | US | claimed |
| CN-118076379-A | Treatment of lupus | 阿斯利康(瑞典)有限公司 | 2024-05-24 | — | — | CN | claimed |
| EP-4337696-A1 | INHIBITOR OF TYPE 1 INTERFERON RECEPTOR STEROID SPARING IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS | Astrazeneca AB (SE) | 2024-03-20 | — | — | EP | claimed |
| CN-117677638-A | Treatment of lupus | 阿斯利康(瑞典)有限公司 | 2024-03-08 | — | — | CN | claimed |
| EP-0036138-B2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1989-10-25 | — | — | EP | claimed |
| EP-0069385-B1 | USE OF EUCALYPTOL FOR ENHANCING SKIN PERMEATION OF BIOAFFECTING AGENTS | MERCK & CO. INC. (US) | 1987-10-14 | — | — | EP | claimed |
| EP-0036138-B1 | COMPOSITION OF MATTER FOR TOPICAL APPLICATION COMPRISING A BIO-AFFECTING AGENT AND N,N-DIETHYL-M-TOLUAMIDE | MERCK & CO. INC. (US) | 1985-08-28 | — | — | EP | claimed |
| EP-0147780-A2 | Drug delivery device | MERCK & CO. INC. (US) | 1985-07-10 | — | — | EP | claimed |
| US-4407792-A | HIGH MOLECULAR WEIGHT ETHYLENE-MALEIC ANHYDRIDE COPOLYMER | ALCON LABORATORIES, INC. (US) | 1983-10-04 | — | — | US | claimed |
| EP-0069385-A2 | Use of eucalyptol for enhancing skin permeation of bioaffecting agents | MERCK & CO. INC. (US) | 1983-01-12 | — | — | EP | claimed |
| EP-0036138-A2 | Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide | MERCK & CO. INC. (US) | 1981-09-23 | — | — | EP | claimed |
| US-4271143-A | ACRYLIC POLYMER GEL | ALCON LABORATORIES, INC. (US) | 1981-06-02 | — | — | US | claimed |
| US-4014335-A | Ocular drug delivery device | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4001388-A | POLYESTERS | ALZA CORPORATION (US) | 1977-01-04 | — | — | US | claimed |